Here we describe the Achilles' Heel Method (AHM), a new function-based approach for identification of inhibitors of signaling pathways, optimized for human cells. The principle of AHM is the identification of 'sensitizing' cDNAs based on their decreased abundance following selection. As a proof of principle, we have employed AHM for the identification of Fas/CD95/APO-1 pathway inhibitors. HeLa cells were transfected with an antisense cDNA expression library in an episomal vector followed by selection with a suboptimal dose of the apoptotic inducer. Antisense inactivation of Fas inhibitors rendered the cells more sensitive to apoptosis resulting in their preferential death and consequent loss of their sensitizing episomes that were identified by subtraction. We show that the resulting products were enriched for sensitizing cDNAs as seven out of eight candidates tested were confirmed as inhibitors of Fas-induced killing either by transfection or by pharmacological inhibition. Furthermore, we demonstrate by multiple approaches that one candidate, NF-E2 related factor 2 (Nrf2), is an inhibitor of Fas-induced apoptosis. Inactivation of Nrf2 by antisense or by a membrane permeable dominantnegative polypeptide sensitized cells while overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, dicumarol, an inhibitor of the phase II detoxifying enzyme NQO1, a downstream target of Nrf2, sensitized cells. Nrf2 induces the production of Glutathione (GSH) and we demonstrated that N-acetyl L-cysteine (NAC), a precursor to GSH, protected cells from Fas-mediated killing. Taken together, AHM is a powerful approach for the identification of inhibitors of a signaling pathway with a low rate of false positives that opens new avenues for function profiling of human genes and discovery of new drug targets.
Introduction
As we conclude the genomic era, efforts are focused on assigning functions to the sequenced genes. Such knowledge is essential for deciphering biological processes and will accelerate identification of new medicines. We have taken a reductionist approach towards the goal of assigning functions to clinically relevant human genes in a rapid and accurate manner. The overall strategy consists of focusing on a signaling pathway that underlies a disease/pathology that can be investigated in tissue culture, using functional genetics to identify pivotal mediators and inhibitors of the pathway, and utilizing pharmacological regulators of the identified genes to modulate the pathway. We chose Fas-induced apoptosis as a signaling pathway with clinical relevance that can be investigated in tissue culture. The pathway is initiated by binding of Fas ligand (FasL) to Fas, a trans-membrane death receptor of the tumor necrosis factor (TNF) super family, followed by a cascade of events that leads in most cell types to apoptosis. (Nagata, 1997; Scaffidi et al., 1998; Ashkenazi and Dixit, 1999; Pinkoski and Green, 1999) . Fas-induced apoptosis is used in physiological processes including killing of virally infected cells, transformed cells and peripheral autoreactive T cells (Nagata, 1997) . Thus, accelerating Fas-induced apoptosis may enhance tumor suppression and ameliorate autoimmunity.
The next step in the reductionist approach is identifying pivotal mediators and inhibitors of the pathway. While classical genetic analyses in prokaryotes and lower eukaryotes led to successful identification of signaling pathway components, similar genetic approaches in mammalian cells have been problematic. To address the gap in function-based gene identification in human cells, we have previously described the Technical Knock Out (TKO) method (Deiss and Kimchi, 1991) for the identification of mediators of apoptosis in human cells. TKO is based on random inactivation of genes via the introduction of an antisense cDNA library, followed by a strong forward selection for the loss of a response to a killing signal. The antisense library is expressed from an episomal shuttle vector that is optimized for efficient introduction, expression and retrieval from human cells (Deiss and Kimchi, 1991) . TKO has been successfully used to identify seven mediators of IFN-g-induced apoptosis, five of which were novel and termed Death-Associated Proteins (DAP) (Deiss et al., , 1996 Kissil et al., 1995; Levy-Strumpf et al., 1997) . Subsequently, others have described genetics screens in mammalian cells based on selections for loss of a phenotype including gene inactivation mediated by antisense or by dominant negative gene fragments (GSE, Death Trap and MarX), retroviral insertions (RHKO) and others (for reviews see Kimchi, 1998; Stark and Gudkov, 1999) .
Comprehensive dissection of the apoptotic signaling requires the identification of mediators as well as inhibitors. Several such inhibitors have been cloned by the introduction of an expression library followed by a strong positive selection for resistance to apoptosis (Hitoshi et al., 1998; Maestro et al., 1999) . To our knowledge, a genetic screen for identification of inhibitors based on their decrease in abundance following selection has not been previously described in human cells. This strategy is technically more challenging because inactivation of the inhibitors renders cells more sensitive to killing and such cells are preferentially lost from the population under the selection conditions.
Here we report the design and validation of the Achilles' Heel Method (AHM), a function-based tool for the identification of inhibitors of apoptosis that does not require any knowledge of gene sequences and is optimized for human cells. Similar to TKO, it is based on random inactivation of genes by transfection of an antisense cDNA library in an episomal vector. However, in contrast to TKO that utilizes a selection for resistance to apoptosis, AHM utilizes a selection for death of the sensitized cells at a suboptimal dose of an apoptotic inducer followed by identification of the sensitizing cDNA fragments. Our results demonstrate that it is feasible to design an AHM screen for a desired apoptotic pathway and identify inhibitors of the pathway with a low rate of false positives. AHM can be easily adapted to identify genes that regulate a wide variety of phenotypes.
Results

AHM design and validation
The AHM protocol used to identify inhibitors of the Fas pathway is illustrated in Figure 1 . HeLa cells were transfected with an antisense expression library containing approximately 100,000 elements cloned in the episomal vector pTKO-1 (expressing Hygromycin B resistance) as previously described (Deiss and Kimchi, 1991) . Following transfection and selection with Hygromycin B, the resistant cell population was further propagated in the presence of Hygromycin B for 2 weeks to ensure the elimination of cells harboring Figure 1 AHM design. An antisense library in an episomal vector was transfected into human cells. Different colored cells represent different antisense cDNAs. Cells expressing antisense cDNAs were expanded (pool 1), treated with suboptimal dose of a selection pressure and the surviving cells were collected (pool 2). Cells that harbored sensitizing cDNAs were more sensitive to killing and thus are not present in pool 2. Episomes were extracted from pool 1 cells as well as from pool 2 cells followed by PCR amplification of the cDNA inserts. PCR products of pool 2 were subtracted from pool 1 and the products were cloned and individually tested in HeLa cells deleterious inactivation events. The pool of Hygromycin-resistant cells (pool 1, Figure 1 ) was treated with a suboptimal dose of an anti-Fas agonistic antibody that resulted in approximately 30-40% killing (data not shown). Surviving cells were collected (pool 2, Figure 1 ), episomes from pool 1 and pool 2 cells were extracted and the cDNA inserts were amplified by polymerase chain reaction (PCR). We predicted that cells expressing sensitizing cDNAs that rendered them more sensitive to killing would be present in pool 1 but not in pool 2. Consequently, sensitizing cDNAs would be preferentially found in the PCR products derived from pool 1 but not in those derived from pool 2. To test this prediction, we subtracted the PCR products of pool 2 from the PCR products of pool 1. The resulting fragments were cloned in pTKO-1 in a directional fashion that reconstructed their orientation in the library. Five clones were at first randomly chosen for validation. Subsequent sequence analysis revealed that three of the cDNA inserts are derived from genes encoding proteins of unknown function and two from transcription factors: Nuclear factor of activated T cells (NFAT5) and Nrf2 (Table 1) . Following sequence analysis of additional clones, we also chose to test three other identified cDNA fragments corresponding to basic fibroblast growth factor (bFGF) and the chapernes Hsp90a and Hsp90b (Table 1) . We became interested in bFGF based on the report that soluble bFGF protects murine cells from Fas-induced killing (Kazama and Yonehara, 2000) and in Hsp90 since a pharmacological inhibitor of Hsp90 that should mimic the anti sense activity was available. At the same time of our studies, none of the eight genes had been implicated in the Fas pathway in HeLa cells.
Sequence analysis revealed that seven of the eight cDNA fragments in Table 1 were cloned in an antisense orientation while the fragment corresponding to NFAT5 was cloned in the sense orientation. While the library was constructed in an antisense orientation (Deiss and Kimchi, 1991) , we have previously identified in the library a functionally active cDNA fragment in the sense orientation and have shown that it likely acts in a dominant negative manner (Levy-Strumpf et al., 1997) .
The ability of each of the cDNA fragments to individually sensitize HeLa cells to Fas-induced apoptosis was tested by transfection experiments. Two independent pools of HeLa cells were generated by transfection with either control episomal vector or with each of the plasmids (Table 1 ) and then treated with a suboptimal dose of anti-Fas antibody. At 17 h posttreatment the number of viable cells was counted. As illustrated in Figure 2b -f, cells transfected with pLPD598, pLPD599, pLPD606, pLPD680, or pLPD737 were significantly more sensitive to Fas-induced killing compared to cells transfected with control vector (Figure 2a ). This increased sensitivity was not a result of impaired growth, since only minor alterations were detected in the growth rates of untreated transfected cells compared to the untreated vector-transfected cells. In contrast, cells transfected with plasmid pLPD681 were not sensitized to Fas-induced killing at 40 h posttreatment with anti-Fas antibodies ( Figure 2g ). As a positive control, we demonstrate that cells transfected with the anti-apoptotic gene CrmA were resistant to Fas-induced killing (Figure 2h ) (Tewari et al., 1995) . We next predicted that inhibition of the anti-apoptotic candidates by pharmacological agents would sensitize cells to apoptosis similar to the effect exerted by antisense. Indeed, geldanamycin (GA), an inhibitor of Hsp90 (Whitesell et al., 1994) sensitized HeLA cells to Fas-induced apoptosis (data not shown). Currently, a derivative of GA, 17 allylaminogeldanamycin (Neckers, 2002) .
Thus, our results validate the conceptual aspects of AHM that sensitizing cDNA can be readily identified by subtraction. Moreover, we have confirmed that the products of the subtraction are enriched for sensitizing cDNAs as seven out of eight candidates that were tested were confirmed as inhibitors of Fas-induced apoptosis in HeLa cells.
Nrf2 is an inhibitor of Fas-induced apoptosis in HeLa cells
We have next focused on one candidate gene identified through AHM, Nrf2, that belongs to the Cap-n-collar (CNC) family of basic region leucine-zipper transcription factors (Moi et al., 1994) . In response to xenobiotics, anti-oxidants and oxidants, Nrf2 upregulates the transcription of genes containing a 5 0 -upstream antioxidant/electrophile responsive element (ARE/ EpRE) by binding to it in a heterodimeric form with other transcription factors. Studies of Nrf2 null mice show that Nrf2 is required for the basal and inducible expression of phase II detoxifying enzymes and oxidative stress responsive genes (Itoh et al., 1997; Chan and Kan, 1999; Ishii et al., 2000) . Phase II detoxifying genes such as NAD(P)H quinone oxidoreductase (NQOI) and Glutathione S-transferase (GST) (Venugopal and Jaiswal, 1996; Itoh et al., 1997; Wasserman and Fahl, 1997) catalyze the deoxification of xenobiotics, drugs and carcinogens (for reviews see Joseph et al., 1994; Meyer, 1996; Begleiter et al., 1997; Salinas and Wong, 1999) . The oxidative stress responsive genes regulated by Nrf2 including superoxide dismutase, g-glutamylcysteine synthetase (g-GCS) and cysteine membrane transport (system x À c ) play a role in the defense against oxidative stress by neutralizing compounds capable of generating reactive oxygen species (ROS) (Itoh et al., 1997; Chan and Kan, 1999; Ishii et al., 2000) . A major defense mechanism against ROS is mediated by reduced glutathione (GSH). The rate-limiting enzyme in the de novo synthesis of GSH is g-GCS. Nrf2 participates in elevating the endogenous levels of GSH by upregulating the genes involved in its production, namely g-GCS (Moinova and Mulcahy, 1999) and cysteine membrane transport system (Ishii et al., 2000) . Thus, Nrf2 regulates Since HeLa cells transfected with an antisense Nrf2 expression vector are significantly more sensitive to Fasinduced apoptosis compared to control cells (Figure 2e , a), we tested whether this sensitivity correlates with reduced levels of Nrf2 protein exerted by the antisense. As shown in Figure 3 , a reduction in the level of Nrf2 protein is observed in two cell lines transfected with antisense Nrf2. This result is in agreement with our previous reports that expression of antisense fragments to DAP-1, DAP-kinase, DAP-3 or cathespin D results in reduced levels of the corresponding proteins (Deiss et al., , 1996 Kissil et al., 1995) . Noteworthy is the observation that while equal amounts of protein were loaded in each lane (Figure 3 ), elevated levels of actin were reproducibly detected in antisense expressing cells. Interestingly, elevated levels of b-actin mRNA were reported in the intestine of Nrf2 ablated mice suggesting that Nrf2 either directly or indirectly regulates the level of b-actin (Itoh et al., 1997) .
To further confirm that Nrf2 is an inhibitor of Fasinduced killing we have utilized diverse approaches as described below.
Dominant negative form of Nrf2 sensitizes cells to Fasinduced apoptosis
To further elucidate the mechanism by which Nrf2 sensitizes cells to Fas-mediated apoptosis we asked whether the ability of Nrf2 to regulate transcription is required. Ohtsubo and colleagues reported that expression of a carboxyl fragment of Nrf2, containing the DNAbinding domain but lacking the activation domain, acts in a dominant negative fashion to inhibit the transcription activation activity of Nrf2 (Ohtsubo et al., 1999) . We tested whether the inactivation of Nrf2 by the dominant negative (DN) fragment will resemble the inactivation by antisense and would result in sensitization to Fas-induced killing. As a means of transient delivery of DN-Nrf2, we employed the 11-amino-acid protein transduction domain (PTD) from the human immunodeficiency virus (HIV) TAT protein that enables rapid, concentration dependent, protein transduction into a wide variety of cells, independent of receptors and transporters (Schwarze et al., 1999) . We have generated a construct expressing a fusion between the reported DN-Nrf2 fragment and the 11-amino-acid PTD from the HIV TAT protein. Recombinant proteins were purified from bacteria, applied to HeLa cells and Fasinduced killing was assessed by DAPI staining. As shown in Figure 4a , treatment with PBS or with two different concentrations of control TAT-GFP protein resulted in Pharmacological modulation of the sensitivity of HeLa cells to Fas-induced apoptosis In order to demonstrate the potential of AHM to identify new drug targets we asked whether drugs that act on the Nrf2 pathway could modulate the sensitivity of HeLa cells to Fas. In the absence of known pharmacological agents specific to Nrf2, we utilized drugs that abrogate or enhance downstream activities regulated by Nrf2. First we predicted that inhibition of NQOI, which is transcriptionally induced by Nrf2, would resemble the antisense inactivation of Nrf2 and would result in increased sensitivity of HeLa cells to Fas-mediated apoptosis. NQOI catalyzes two-electron reduction of quinones and their derivatives utilizing NADH or NADPH as an electron donor. Dicumarol inhibits NQOI activity by competing with NADH or NADPH for binding to the oxidized form of NQOI (Hosoda et al., 1974) . HeLa cells were treated with or without anti-Fas antibody and dicumarol and percent apoptotic cells were measured by DAPI staining. As shown in Figure 5a , dicumarol potentiated Fas-induced killing in a dose-dependent manner. Treatment of cells with antiFas antibody in the presence of vehicle alone or 25 mm dicumarol resulted in approximately 22% apoptotic cells, while treatment with 100 mm resulted in approximately 97% We next predicted that enhancing the activities that are upregulated by Nrf2 would protect HeLa cells from Fasinduced apoptosis, similar to overexpression of Nrf2. Since Nrf2 upregulates genes that produce and utilize GSH, we have mimicked this activity of Nrf2 by increasing the level of GSH by treatment with NAC, a precursor of cysteine and GSH. Indeed, as shown in Figure 5b , treatment with NAC completely abrogated Fas-induced killing of HeLa cells. Taken together, our data demonstrate that Nrf2 is an inhibitor of the Fas pathway and pharmacological agents that modulate Nrf2-regulated activities correspondingly modulate the sensitivity of HeLa cells to Fas-induced apoptosis.
Discussion
In this study, we have designed and validated AHM as a new approach for identifying inhibitors of Fas-induced apoptosis with a low rate of false positives. AHM can be broadly used to identify inhibitors of any selectable pathway in an unbiased 'function-based' manner. It does not require a priori knowledge of any gene sequences and is optimized for human cells. In combination with TKO, comprehensive identification of all nonredundant elements in a specific pathway in human cells becomes as easy as dissecting a signaling pathway in lower eukaryotic or prokaryotic systems. In this study, a relatively small-scale AHM was performed. It includes a genetic screen of a library containing approximately 100,000 elements followed by subtraction. Technically, it is feasible to scale up the AHM screen by using high throughput tools such as gene microarrays for a myriad of applications.
As a proof of principle, we tested eight clones that were identified by subtraction and show that seven of them are inhibitors of Fas-induced killing. Whether these genes are directly involved in the Fas pathway or are involved in other signaling pathways that interact with the Fas pathway is yet to be determined. The identified genes include three proteins of previously unknown function (NM_017816.1, NM_024647.1, XM_029734); bFGF, in accordance with previous reports that bFGF protects cells from Fas-and TNFmediated apoptosis (Kazama and Yonehara, 2000) ; Hsp90, in agreement with reports demonstrating that it regulates the stability of various proteins including numerous ones that exert antiapoptotic activities such as Fak, MEK, protein kinase CK-II and Receptor Interacting Protein (RIP) (reviewed in Richter and Buchner, 2001 ) and NFAT5 that is involved in regulating osmotic stress-induced genes (Miyakawa et al., 1999; Ko et al., 2000) .
We have focused on Nrf2 and utilized different methods to unequivocally demonstrate that it is a new inhibitor of the Fas pathway in human cells. Our data show that inactivation of Nrf2 by antisense in stably transfected cells or transiently by DN-Nrf2-TAT sensitized cells to apoptosis. Conversely overexpression of Nrf2 protected cells from Fas. We further examined the consequences of modulating two activities regulated by Nrf2, namely NQOI and GSH production. Transcription of NQOI is directly regulated by Nrf2 in response to a variety of agents (for a review, see Jaiswal, 2000) and NQOI activity plays an important role in the defense mechanism against the cytotoxicity of quinones and oxidative stress. We show that treatment with dicumarol, an inhibitor of NQOI, sensitized HeLa cells to Fas killing. This result is in agreement with earlier findings concerning the effect of dicumarol on apoptosis: it strongly potentiates TNF-a-induced apoptosis in HeLa cells (Cross et al., 1999) ; it abrogates the suppression of apoptosis by IGF-I in FL5.12 cells overexpressing wide-type (wt) insulin-like growth factor I receptor (IGF-IR) and it induces apoptosis in MCF-7 cells (Krause et al., 2001) . Contradictory are the reports that overexpression of NQOI in MCF-7 sensitizes cells to TNF-a (Siemankowski et al., 2000) and that dicumarol blocks wt p53-mediated apoptosis in girradiated normal thymocytes and in Ml myeloid leukemic cells that overexpress wt p53 (Asher et al., 2001) . Thus, the effect of dicumarol on apoptosis appears to be specific to cell type as well as to the apoptotic stimuli. The mechanism underlying the sensitization of HeLa cells to Fas-induced apoptosis by dicumarol is yet to be determined. It is possible that in HeLa cells the basal levels of NQOI activity mediate a dicumarol sensitive, survival pathway. This pathway could be mediated by the survival factor NFkB as dicumarol inhibits NFkB activation in primary macrophages (Cross et al., 1999) . Another potential mediator of this survival pathway is the mitogen-activated protein kinase (MAPK) as it was reported that dicumarol blocks MAPK activation in HeLa cells (Cross et al., 1999) and inhibition of the MAPK cascade sensitizes HeLa cells to Fas-induced apoptosis (Holmstrom et al., 1999) . Interestingly, extracellular-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK) have been implicated in ARE activation in a complex network that suggest ARE specificity, inducer specificity and cell type/tissue specificity (Yu et al., 1999 (Yu et al., , 2000a .
The observation that NAC fully protects HeLa cells from apoptosis is an interesting one. Besides the activity of NAC as a precursor to GSH it exhibits a spectacular array of effects that reflect its antioxidant activity. NAC modulates metabolism, DNA repair, gene expression, signal transduction, inhibition of cell transformation, anti-inflammatory activity and cell cycle progression. NAC also inhibits apoptosis in a variety of systems including those induced by Fas (for a review, see De Flora et al., 2001) . Thus, our results are in agreement with the current notion of the protective effect of NAC. To the best of our knowledge, our study is the first to show protective effect of NAC against Fas-induced apoptosis in HeLa cells. Our results suggest that the cellular oxidative state plays an important role in Fas-induced apoptosis in HeLa cells either by directly transmitting the signals or by maintaining a permissive environment for signaling as previously reported in other systems (Cross et al., 1999; Siemankowski et al., 2000) . Thus, while our data show that Nrf2 inhibits Fas-induced apoptosis, further studies would determine whether this inhibition is mediated by regulation of the sensitivity to oxidative stress or by direct regulation of the components in the Fas signaling pathway.
Taken together, our findings validate the concept of the reductionist approach that identifying negative regulator(s) of a signaling pathway by AHM could contribute to the rapid identification of drug targets.
Materials and methods
Cell lines and plasmids
HeLa cells were grown in Dulbecco's modified Eagle medium (GIBCO/BRL, Rockville, MD, USA) supplemented with 10% fetal bovine serum (Hyclone), 2 mm glutamine, 100 U/ml pencillin and 0.1 mg/ml streptomycin (GIBCO/BRL). CrmA expressing cells were generated by transfection of the expression construct pcDNA3-crmA (kindly provided by Dr Dixit, Genentech inc., South San Francisco, CA, USA) into HeLa cells and selection in G418. pTKO-1 plasmid was described earlier (Deiss and Kimchi, 1991) . Human Nrf2 was kindly provided by Dr Kan, University of California San Francisco, San Francisco, CA, USA. TAT-DN-Nrf2 was generated by cloning a fragment of human Nrf2 encoding amino acid 367-589 between the Kpnl and EcoRI restriction sites of the bacterial expression vector pTAT-HA kindly provided by Dr Dowdy, University of Washington, St Louis, MO, USA.
AHM protocol
HeLa cells (10 6 cells/100 mm plate) were transfected with 15 mg of antisense cDNA library in pTKO-1 (Deiss and Kimchi, 1991) by SuperFect transfection reagent (Qiagen). Two days later cells were treated with 200 mg/ml Hygromycin B (Calbiochem) for 2 weeks during which transfected cells carrying lethal antisense cDNAs fragments were eliminated. Hygromycin R cells (2.5 Â 10 6 ) were plated in a 150 mm plate 24 h prior to treatment with 10 ng/ml anti-human Fas antibody (clone CH-11, catalog number MC-060, Kamiya Biomedical Company) (pool 2). Five days post treatment approximately 30-40% of the cells were killed as estimated by microscopic examination. A parallel culture was grown in the absence of anti-Fas antibody (pool 1). After 5 days, pool 1 as well as pool 2 cells were washed twice with PBS, scraped off the plate and stored as pellets at À801C. Frozen cell pellets were lysed by addition of 200 ml of solution P1, followed by 200 ml of solution P2 and 200 ml of solution P3 (as described by the manufacturer, plasmid maxi kit, Qiagen). Following 5 min incubation on ice, the lysate was centrifuged for 10 min at 15,000 Â g, the supernatant was mixed with an equal volume of isopropanol and centrifuged at 15,000 Â g for 10 min. The DNA pellet was rinsed with 70% ethanol and resuspended in 100 ml of water. The cDNA inserts were amplified by PCR in a 100 ml reaction contaning: 1 ml DNA, 200 mm of dATP, dGTP, dCTP, dTTP; 10 mm Tris-HCL pH 9.0; 0.1% Triton X-100; 1.0 mm MgCl; 1 unit Taq DNA polymerase (GIBCO/BRL) and 500 ng each of primers; prLPD#64(TGGAGGCCTAGGCTTTTGC) and prLPD#65(GTAAGGTTCCTTCACAAGGATCC). These primers are derived from the sequences that flank the cDNA insertion site in the pTKO-1 antisense expression vector. The primers are designed to restore a HindIII restriction site on the promter proximal side of the cDNA and a BamHI site on the promoter distal side to conserve the orientation of the cDNA fragments upon their cloning in pTKO-1. The reaction was incubated 941C for 5 min; subjected to 25 cycles (941C for 1 min, 581C for 1 min and 721C for 5 min), followed by 721C for 7 min.
Subtraction
The PCR products of the AHM were cleaved by BamHI and HindIII, purified (Wizard PCR Preps, Promega) and subtracted (PCR-Select cDNA subtraction kit, Clontech). The driver for the subtraction was the product of the PCR reaction derived from the treated cells (pool 2) and the tester was derived from untreated cells (pool 1). The following modifications to the manufacturer's instructions were made. (1) The first step was IV F 3, since no cDNA synthesis is required. (2) The blunt ends adapters 1 and 2R were replaced with cohesive ends adapters as follows: Adapter I was replaced by a mixture of primers prLPD#80 (CTAATACGACTCACTATAGGGC-TCGAGCGGCCGCCCGGGCAGGTA), prLPD#81 (CT-AATACGACTCACTATAGGGCTCGAGCGGCCGCCC-GGGCAGGTG), pr LPD#83 (AGCTTACCTGCCCGG) and prLPD#84(GATCCACCTGCCCGG). Adapter 2R was replaced by a mixture of prLPD#82 (CTAATACGACTCAC-TATAGGGCAGCGTGGTCGCGGCCGAGGTG), prLPD-#88 (AGCTTACCTCGGCCG) prLPD#89 (GATCCACCT-CGGCCG) and prLPD#90 (CTAATACGACTCACTATAG-GGCAGCGTGGTCGCGGCCGAGGTA). The replacement was performed to maximize the ligation efficiency and to allow directional cloning of the cDNAs following subtraction. For the adapter ligation 0.3 mg of the tester was used. (3) The initial hybridization included 0.9 mg of the driver and 0.03 mg of the adapted ligated tester. The products of the subtraction were cleaved with BamHI and HindIII, purified and cloned between BgIII and HindIII sites in pBlueScript (for sequencing) or pTKO-1 (for transfections).
Transfections and bioassay
HeLa cells (2 Â 10 6 cells/100 mm plate) were plated 20 h prior transfection with either 17 mg of antisense expressing vector or with control vector harboring no cDNA insert, by calcium phosphate precipitation. Forty-eight hours post transfection, cells were treated with 200 mg/ml Hygromycin B for 2 weeks followed by establishment of cell lines. For bioassays, antisense transfected cells or control vector transfected cells (1.6 Â 10 5 cells/well in six-well plates) were plated in duplicates 20-24 h prior to the treatment with 200 ng/ml anti-Fas antibody. Seventeen hours post-treatment, the number of viable, trypan blue (GIBCO/BRL) excluding cells that remained attached to the plate following rinsing with PBS was determined.
Transient transfection
HeLa cells (0.3 Â 10 6 cells/well in six-well plate) were plated 24 h prior to co-transfection with either 3 mg of pcDNA 3.1 expressing Nrf2 or control vector pcDNA 3.1 and 1 mg of b-glalactosidase expressing plasmid, pCMV-b-Gal for the identification of the transfected cells. Transfection was performed in duplicate by using lipofectamine plus reagent (GIBCO/BRL) according to the manufacturer's instructions. Seven hours after the addition of DNA, cells were treated with 200 ng/ml anti-Fas antibody for 17 h. For detection of b-gal activity cells were rinsed twice with PBS, fixed with 0.5% glutaradehyde for 15 mins, rinsed twice with PBS and stained in X-gal buffer (0.2% X-gal, 0.2% NP40, 1 mm MgCl 2 , 3.3 mm K 3 Fe(CN) 6 , 3.3 mm K 4 Fe(CN) 6 in PBS) for 1 h or until blue cells were visible. The reaction was stopped by rinsing with PBS and adding 50% glycerol. Cell death was assessed by microscopic examination of the morphology of b-gal expressing, blue cells. Round cells, loosely attached to the plate were scored as apoptotic. For the calculation of percent apoptotic cells, three fields were counted from each well.
Purification of DN-Nrf2
The recombinant protein pTAT-HA-GFP (kindly provided by Dr Dowdy, University of Washington, St Louis) and TAT-DN-Nrf2 were produced in bacteria and purified as described (Schwarze et al., 1999) . The concentration of the purified protein was estimated by SDS-PAGE by comparing to standard BSA, following coomasie staining.
Treatment with DN-Nrf2 and apoptosis assay
HeLa cells, 8.3 Â 10 4 cells/well, were plated in 12-well plates in duplicate 20-24 h prior to treatment with various concentrations of recombinant TAT-DN-Nrf2 protein, TAT-GFP protein or PBS. An hour after treatment, cells were treated with 200 ng/ml anti-Fas antibody. After 20 h, the cells were fixed by slowly adding 1/3 volume of formaldehye (37%) to the medium. Twenty four hours after fixation the cells were gently washed twice with PBS and stained with 2.5 mg/ml DAPI (4 0 ,6-diamidino-2-phenylindole, Sigma D-9542) in PBS for 5 min, followed by two washes in PBS. Stained cells were viewed with a Leica DMIRB fluorescent inverted microscope. At each time point, eight fields of at least 300 cells in total were scored.
Treatment of HeLa cells with NAC
Cells (8.3 Â 10 4 cells/well) were plated in six well plates in duplicates 20-24 h prior to treatment with various concentrations of NAC (Sigma/Aldrich) in the presence or absence of 50 ng/ml anti-Fas antibody. Five days post-treatment the number of viable, trypan blue excluding cells that remained attached to the plate following rinsing with PBS was determined.
Treatment of HeLa cells with dicumarol
Cells (1.6 Â 10 5 cells/well) were plated in six well plates in duplicates. After 13-15 h, cells were treated with various concentrations of dicumarol (Sigma/Aldrich) or vehicle (0.2 mm NaOH) in the absence or presence of 200 ng/ml antihuman Fas antibody. The latter was added 15 min later. Seventeen hours post treatment the cells were stained with DAPI and analyzed as described above.
Western analysis
Antisense transfected cells or control vector transfected cells were plated at a density of 2.5 Â 10 6 cells/150 mm plate. After 24 h, the cells were rinsed with PBS and lysed in RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) in the presence of protease inhibitor cocktail mix (Roche Diagnostics, GmbH). Samples containing equal amounts of protein were separated by SDS-PAGE and transferred to nitrocellulose membranes. The immunoblots were probed with primary antibody and incubated with secondary antibody conjugated to horseradish peroxidase (Pierce) followed by incubation with SuperSignal chemiluminescent substrate (Pierce). Following exposure of the membranes to X-ray film, the antibodies were removed (Amersham, ECL Western blotting protocols) and the membranes were reacted with the next primary antibody. The following primary anti-bodies were used: anti-Nrf2 antibody (Santa Cruz sc722, 1:200), anti-actin antibody (Sigma A5441 (1:10,000)) and anti-tubulin antibody (Sigma T9026, 1:10,000).
